Significance of serum osteoprotegerin and receptor activator of nuclear factor κb ligand in Japanese prostate cancer patients with bone metastasis

International Journal of Clinical Oncology

Volumn 16, Issue 4, 2011, Pages 366-372

  Kamiya, Naoto ^a   Suzuki, Hiroyoshi ^a   Endo, Takumi ^a   Takano, Makoto ^a   Yano, Masashi ^a   Naoi, Makito ^a   Kawamura, Koji ^b   Imamoto, Takashi ^b   Takanami, Masaharu ^a   Ichikawa, Tomohiko ^b  

^a TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Bone metastasis; Osteoprotegerin; Prostate cancer; Receptor activator of nuclear factor B ligand

Indexed keywords

MEDRONATE TECHNETIUM TC 99M; OSTEOPROTEGERIN; PROSTATE SPECIFIC ANTIGEN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TUMOR MARKER;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BONE METASTASIS; BONE SCINTISCANNING; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER STAGING; CAUSE SPECIFIC SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; HUMAN; JAPANESE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RADIOGRAPHY; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; BONE NEOPLASMS; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOPLASM STAGING; OSTEOPROTEGERIN; PROSTATIC NEOPLASMS; RANK LIGAND; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 80052773257     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0193-7     Document Type: Article

References (30)

1. RE Coleman 1997 Skeletal complications of malignancy Cancer 80 1588 1594 9362426 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G 1:STN:280:DyaK1c%2Fis1Onuw%3D%3D (Pubitemid 27444031)
2. MG Oefelein V Ricchiuti W Conrad, et al. 2002 Skeletal fractures negatively correlate with overall survival in men with prostate cancer J Urol 168 1005 1007 12187209 10.1016/S0022-5347(05)64561-2
3. RE Coleman 2001 Metastatic bone disease: clinical features, pathophysiology and treatment strategies Cancer Treat Rev 27 165 176 11417967 10.1053/ctrv.2000.0210 1:CAS:528:DC%2BD3MXktlCktb4%3D (Pubitemid 32452017)
4. P Sabbatini SM Larson A Kremer, et al. 1997 Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer J Clin Oncol 17 948 957
5. D Corrie JH Timmons JM Bauman, et al. 1988 Efficacy of follow-up bone scans in carcinoma of the prostate Cancer 61 2453 2454 3130180 10.1002/1097-0142(19880615)61:12<2453::AID-CNCR2820611211>3.0.CO;2-P 1:STN:280:DyaL1c3htVahtw%3D%3D
6. JE Oesterling SK Martin EJ Bergstralh, et al. 1993 The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer JAMA 269 57 60 7677962 10.1001/jama.269.1.57 1:STN:280: DyaK3s7gtVyrsw%3D%3D (Pubitemid 23006523)
7. S Akimoto Y Furuya K Akakura, et al. 1999 Inability of bone turnover marker as a strong prognostic indicator in prostate cancer patients with bone metastasis: comparison with the extent of disease (EOD) grade Prostate 38 28 34 9973106 10.1002/(SICI)1097-0045(19990101)38:1<28::AID-PROS3>3.0.CO;2-M 1:STN:280:DyaK1M7jsleqsw%3D%3D (Pubitemid 29011014)
8. C Ozu J Nakashima Y Horiguchi, et al. 2008 Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate-specific antigen in patients with prostate cancer Int J Urol 15 419 422 18452459 10.1111/j.1442-2042.2008.02029.x 1:CAS:528:DC%2BD1cXpvVWmtrs%3D (Pubitemid 351623897)
9. A Hegele HG Wahl Z Varga, et al. 2007 Biochemical markers of bone turnover in patients with localized and metastasized prostate cancer BJU Int 99 330 334 17092281 10.1111/j.1464-410X.2006.06604.x 1:CAS:528:DC%2BD2sXjt1Kgtro%3D (Pubitemid 46103111)
10. Y Miyaji T Saika Y Yamamoto, et al. 2004 Effects of gonadotropin- releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer Urology 64 128 131 15245949 10.1016/j.urology.2004.03.012 (Pubitemid 38887592)
11. N Kamiya H Suzuki T Endo, et al. 2010 Implications of serum bone turnover markers in prostate cancer patients with bone metastasis Urology 75 1446 1451 20206975 10.1016/j.urology.2009.11.049
12. JM Brown RL Vessella PJ Kostenuik, et al. 2001 Serum osteoprotegerin levels are increased in patients with advanced prostate cancer Clin Cancer Res 7 2977 2983 11595685 1:CAS:528:DC%2BD3MXnvF2ktbc%3D (Pubitemid 32963814)
13. LM Demers 2003 Bone markers in the management of patients with skeletal metastases Cancer 97 874 879 12548589 10.1002/cncr.11127 (Pubitemid 36125826)
14. J Zhang J Dai Y Qi, et al. 2001 Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone J Clin Invest 107 1235 1244 11375413 10.1172/JCI11685 1:CAS:528: DC%2BD3MXjsl2ntr0%3D (Pubitemid 32494540)
15. JM Brown E Corey ZD Lee, et al. 2001 Osteoprotegerin and rank ligand expression in prostate cancer Urology 57 611 616 11306358 10.1016/S0090-4295(00) 01122-5 1:STN:280:DC%2BD3M3ms1WrsQ%3D%3D
16. K Jung M Lein C Stephan, et al. 2004 Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications Int J Cancer 111 783 791 15252851 10.1002/ijc.20314 1:CAS:528:DC%2BD2cXmvVenu7s%3D (Pubitemid 39062904)
17. MS Soloway SW Hardeman D Hickey, et al. 1988 Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan Cancer 61 195 202 3334948 10.1002/1097-0142(19880101)61:1<195::AID- CNCR2820610133>3.0.CO;2-Y 1:STN:280:DyaL1c%2FnvFyltw%3D%3D (Pubitemid 18023133)
18. F Saad DM Gleason R Murray, et al. 2002 Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 94 1458 1468 12359855 1:CAS:528:DC%2BD38XosVans7g%3D
19. JA Smith Jr PH Lange RA Janknegt, et al. 1997 Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate J Urol 157 1329 1334 9120932 10.1016/S0022-5347(01)64963-2 (Pubitemid 27130808)
20. N Koopmans IJ de Jong AJ Breeuwsma, et al. 2007 Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach J Urol 178 849 853 17631330 10.1016/j.juro.2007.05.029 1:CAS:528:DC%2BD2sXhtValtrbM (Pubitemid 47211070)
21. N Bucay I Sarosi CR Dunstan, et al. 1998 Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification Genes Dev 12 1260 1268 9573043 10.1101/gad.12.9.1260 1:CAS:528:DyaK1cXjtVejsrs%3D (Pubitemid 28213402)
22. WC Dougall M Glaccum K Charrier, et al. 1999 RANK is essential for osteoclast and lymph node development Genes Dev 13 2412 2424 10500098 10.1101/gad.13.18.2412 1:CAS:528:DyaK1MXmsVCgtr4%3D (Pubitemid 29453612)
23. G Eghbali-Fatourechi S Khosla A Sanyal, et al. 2003 Role of RANK ligand in mediating increased bone resorption in early postmenopausal women J Clin Invest 111 1221 1230 12697741 1:CAS:528:DC%2BD3sXjtFCrs7g%3D (Pubitemid 36519939)
24. DM Anderson E Maraskovsky WL Billingsley, et al. 1997 A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function Nature 13 175 179 10.1038/36593 1:STN:280:DyaK2szisFWgtw%3D%3D (Pubitemid 27507987)
25. DL Lacey E Timms HL Tan, et al. 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 165 176 9568710 10.1016/S0092-8674(00)81569-X 1:CAS:528:DyaK1cXivVyhtrg%3D (Pubitemid 28180851)
26. H Yasuda N Shima N Nakagawa, et al. 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL Proc Natl Acad Sci USA 95 3597 3602 9520411 10.1073/pnas.95.7.3597 1:CAS:528:DyaK1cXitlKjsLY%3D (Pubitemid 28173173)
27. G Chen K Sircar A Aprikian, et al. 2006 Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation Cancer 107 289 298 16752412 10.1002/cncr.21978 1:CAS:528:DC%2BD28Xnsl2mtL0%3D (Pubitemid 44036558)
28. K Jung C Stephan A Semjonow, et al. 2003 Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer J Urol 170 2302 2305 14634401 10.1097/01.ju.0000094191.39574.cb (Pubitemid 37413980)
29. G Mountzios MA Dimopoulos A Bamias, et al. 2007 Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton Acta Oncol 46 221 229 17453373 10.1080/02841860600635870 1:CAS:528:DC%2BD2sXjs1GlsLc%3D
30. JJ Body P Greipp RE Coleman, et al. 2003 A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases Cancer 97 887 892 12548591 10.1002/cncr.11138 (Pubitemid 36125828)